In a blog post today, Pharmalot delves into various opinions on biopharmaceutical research and development (R&D) spending.
Most Recent Posts
Today we're featuring a blog post from Val Halamandaris, the President of the National Association for Home Care and Hospice (NAHC).
With the start of the next round of negotiations for the Trans Pacific Partnership in Leesburg, Virginia many Americans probably do not know how important these talks are to U.S. jobs and exports. The biopharmaceutical sector directly employed more than 650,000 U.S. workers in 2009, supporting a total of 4 million jobs [in areas such as construction, trucking, and information technology.
The clock is ticking as we count down the remaining days until the first ever Research and Hope Award ceremony, where we will have the privilege of honoring individuals who have made incredible sacrifices in the great battle against Alz
Ten thousand baby boomers will turn 65 today. This will happen again tomorrow, the next day and every day until 2030. With such a significant growth in Medicare eligible Americans, ensuring effective coverage and access to medicines well into the future is a priority.
A strong U.S. biopharma industry is vital to ensuring the health of our nation's economy and citizens. Investment in R&D supports jobs within a variety of U.S. industries. The below infographic explains how only with a strong and growing biopharma sector can we add jobs, reduce long term healthcare costs and prolong the quality of life for all Americans.
For nearly 30 years, PhRMA has held an annual awards event called the Discoverer's Award to honor pioneers in the biopharmaceutical industry whose discoveries helped move the goal post forward in the war against disease. Past recipients were honored for discovering breakthrough medicines for diseases such as cervical cancer, depression, diabetes and HIV/AIDS.